<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1409" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1409/" /><meta name="ncbi_pagename" content="Cerebrotendinous Xanthomatosis - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Cerebrotendinous Xanthomatosis - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Cerebrotendinous Xanthomatosis" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2016/04/14" /><meta name="citation_author" content="Antonio Federico" /><meta name="citation_author" content="Maria Teresa Dotti" /><meta name="citation_author" content="Gian Nicola Gallus" /><meta name="citation_pmid" content="20301583" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1409/" /><meta name="citation_keywords" content="Cerebral Cholesterinosis" /><meta name="citation_keywords" content="CTX" /><meta name="citation_keywords" content="Sterol 26-hydroxylase, mitochondrial" /><meta name="citation_keywords" content="CYP27A1" /><meta name="citation_keywords" content="Cerebrotendinous Xanthomatosis" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Cerebrotendinous Xanthomatosis" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Antonio Federico" /><meta name="DC.Contributor" content="Maria Teresa Dotti" /><meta name="DC.Contributor" content="Gian Nicola Gallus" /><meta name="DC.Date" content="2016/04/14" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1409/" /><meta name="description" content="Cerebrotendinous xanthomatosis (CTX) is a lipid storage disease characterized by infantile-onset diarrhea, childhood-onset cataract, adolescent- to young adult-onset tendon xanthomas, and adult-onset progressive neurologic dysfunction (dementia, psychiatric disturbances, pyramidal and/or cerebellar signs, dystonia, atypical parkinsonism, peripheral neuropathy, and seizures). Chronic diarrhea from infancy may be the earliest clinical manifestation. In approximately 75% of affected individuals, cataracts are the first finding, often appearing in the first decade of life. Xanthomas appear in the second or third decade; they occur on the Achilles tendon, the extensor tendons of the elbow and hand, the patellar tendon, and the neck tendons. Xanthomas have been reported in the lung, bones, and central nervous system. Some individuals show cognitive impairment from early infancy, whereas the majority have normal or only slightly impaired intellectual function until puberty; dementia with slow deterioration in intellectual abilities occurs in the 20s in more than 50% of individuals. Neuropsychiatric symptoms such as behavioral changes, hallucinations, agitation, aggression, depression, and suicide attempts may be prominent. Pyramidal signs (i.e., spasticity) and/or cerebellar signs almost invariably become evident between ages 20 and 30 years." /><meta name="og:title" content="Cerebrotendinous Xanthomatosis" /><meta name="og:type" content="book" /><meta name="og:description" content="Cerebrotendinous xanthomatosis (CTX) is a lipid storage disease characterized by infantile-onset diarrhea, childhood-onset cataract, adolescent- to young adult-onset tendon xanthomas, and adult-onset progressive neurologic dysfunction (dementia, psychiatric disturbances, pyramidal and/or cerebellar signs, dystonia, atypical parkinsonism, peripheral neuropathy, and seizures). Chronic diarrhea from infancy may be the earliest clinical manifestation. In approximately 75% of affected individuals, cataracts are the first finding, often appearing in the first decade of life. Xanthomas appear in the second or third decade; they occur on the Achilles tendon, the extensor tendons of the elbow and hand, the patellar tendon, and the neck tendons. Xanthomas have been reported in the lung, bones, and central nervous system. Some individuals show cognitive impairment from early infancy, whereas the majority have normal or only slightly impaired intellectual function until puberty; dementia with slow deterioration in intellectual abilities occurs in the 20s in more than 50% of individuals. Neuropsychiatric symptoms such as behavioral changes, hallucinations, agitation, aggression, depression, and suicide attempts may be prominent. Pyramidal signs (i.e., spasticity) and/or cerebellar signs almost invariably become evident between ages 20 and 30 years." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1409/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/ctx/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1409/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE89BF73E04154C10000000002700114.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1409_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1409_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/ccm/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/char/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1409_"><span class="title" itemprop="name">Cerebrotendinous Xanthomatosis</span></h1><p class="contrib-group"><span itemprop="author">Antonio Federico</span>, MD, <span itemprop="author">Maria Teresa Dotti</span>, MD, and <span itemprop="author">Gian Nicola Gallus</span>, DSci.</p><a data-jig="ncbitoggler" href="#__NBK1409_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1409_ai__"><div class="contrib half_rhythm"><span itemprop="author">Antonio Federico</span>, MD<div class="affiliation small">Neuroscience<br />University of Siena<br />Siena, Italy<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ti.isinu@ociredef" class="oemail">ti.isinu@ociredef</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Maria Teresa Dotti</span>, MD<div class="affiliation small">Neuroscience<br />University of Siena<br />Siena, Italy<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ti.isinu@ittod" class="oemail">ti.isinu@ittod</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Gian Nicola Gallus</span>, DSci<div class="affiliation small">Neuroscience<br />University of Siena<br />Siena, Italy<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ti.isinu@2sullag" class="oemail">ti.isinu@2sullag</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">July 16, 2003</span>; Last Update: <span itemprop="dateModified">April 14, 2016</span>.</p><p><em>Estimated reading time: 21 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="ctx.Summary" itemprop="description"><h2 id="_ctx_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Cerebrotendinous xanthomatosis (CTX) is a lipid storage disease characterized by infantile-onset diarrhea, childhood-onset cataract, adolescent- to young adult-onset tendon xanthomas, and adult-onset progressive neurologic dysfunction (dementia, psychiatric disturbances, pyramidal and/or cerebellar signs, dystonia, atypical parkinsonism, peripheral neuropathy, and seizures). Chronic diarrhea from infancy may be the earliest clinical manifestation. In approximately 75% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, cataracts are the first finding, often appearing in the first decade of life. Xanthomas appear in the second or third decade; they occur on the Achilles tendon, the extensor tendons of the elbow and hand, the patellar tendon, and the neck tendons. Xanthomas have been reported in the lung, bones, and central nervous system. Some individuals show cognitive impairment from early infancy, whereas the majority have normal or only slightly impaired intellectual function until puberty; dementia with slow deterioration in intellectual abilities occurs in the 20s in more than 50% of individuals. Neuropsychiatric symptoms such as behavioral changes, hallucinations, agitation, aggression, depression, and suicide attempts may be prominent. Pyramidal signs (i.e., spasticity) and/or cerebellar signs almost invariably become evident between ages 20 and 30 years.</p><p>The biochemical abnormalities that distinguish CTX from other conditions with xanthomas include high plasma and tissue cholestanol concentration, normal-to-low plasma cholesterol concentration, decreased chenodeoxycholic acid, increased concentration of bile alcohols and their glyconjugates, and increased concentrations of cholestanol and apolipoprotein B in cerebrospinal fluid.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of CTX is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the above clinical and biochemical findings and/or by the identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>CYP27A1</i>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Long-term treatment with chenodeoxycholic acid (CDCA) normalizes bile acid synthesis, normalizes plasma and CSF concentration of cholestanol, and improves neurophysiologic findings. Inhibitors of HMG-CoA reductase alone or in combination with CDCA are also effective in decreasing cholestanol concentration and improving clinical signs; however, they may induce muscle damage. Coenzyme Q<sub>10</sub> treatment may improve muscle weakness. Cataract extraction is typically required in at least one eye by age 50 years. Epilepsy, spasticity, and parkinsonism are treated symptomatically.</p><p><i>Prevention of primary manifestations:</i> Early treatment with CDCA in presymptomatic individuals appears to prevent clinical manifestations.</p><p><i>Prevention of secondary complications</i>: Calcium and vitamin D supplementation improve osteoporosis.</p><p><i>Surveillance:</i> Annual neurologic and neuropsychological evaluation, cholestanol plasma concentration, brain MRI, echocardiogram, and assessment of total body density (TBD).</p><p><i>Agents/circumstances to avoid:</i> Caution has been suggested with statins.</p><p><i>Evaluation of relatives at risk:</i> Early diagnosis by biochemical testing or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (if the two pathogenic variants in the family are known) allows for early treatment that may prevent or limit disease manifestations.</p><p><i>Pregnancy management:</i> Treatment with chenodeoxycholic acid should not be interrupted during pregnancy.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>CTX is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk family members and prenatal testing for pregnancies at increased risk are possible if both <i>CYP27A1</i> pathogenic variants in the family are known.</p></div></div><div id="ctx.Diagnosis"><h2 id="_ctx_Diagnosis_">Diagnosis</h2><div id="ctx.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Consensus clinical diagnostic criteria for cerebrotendinous xanthomatosis (CTX) have not been published. However, to aid in the diagnosis of CTX, <a class="bk_pop" href="#ctx.REF.mignarri.2014.421">Mignarri et al [2014]</a> have developed a diagnostic flow chart based on an individual&#x02019;s degree-of-suspicion score as determined by clinical, family history, and radiographic findings. See <a class="bk_pop" href="#ctx.REF.mignarri.2014.421">Mignarri et al [2014]</a> (<a href="http://link.springer.com/article/10.1007/s10545-013-9674-3/fulltext.html#Tab2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Table 2. Suspicion index</a> and <a href="http://link.springer.com/article/10.1007/s10545-013-9674-3/fulltext.html#Fig1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Figure 1. Diagnostic flow chart</a>).</p><p>CTX, a lipid storage disease, <b>should be suspected</b> in individuals with the following clinical, radiographic, and laboratory findings:</p><p><b>Clinical features</b></p><ul><li class="half_rhythm"><div>Infantile-onset diarrhea</div></li><li class="half_rhythm"><div>Childhood-onset cataract</div></li><li class="half_rhythm"><div>Adolescent- to young adult-onset tendon xanthomas (<a class="figpopup" href="/books/NBK1409/figure/ctx.F1/?report=objectonly" target="object" rid-figpopup="figctxF1" rid-ob="figobctxF1">Figure 1</a>)</div></li><li class="half_rhythm"><div>Adult-onset progressive neurologic dysfunction (dementia, psychiatric disturbances, pyramidal and/or cerebellar signs, and seizures)</div></li></ul><div class="iconblock whole_rhythm clearfix ten_col fig" id="figctxF1" co-legend-rid="figlgndctxF1"><a href="/books/NBK1409/figure/ctx.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figctxF1" rid-ob="figobctxF1"><img class="small-thumb" src="/books/NBK1409/bin/ctx-Image001.gif" src-large="/books/NBK1409/bin/ctx-Image001.jpg" alt="Figure 1. . Different localization and severity of tendon xanthomas in CTX." /></a><div class="icnblk_cntnt" id="figlgndctxF1"><h4 id="ctx.F1"><a href="/books/NBK1409/figure/ctx.F1/?report=objectonly" target="object" rid-ob="figobctxF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Different localization and severity of tendon xanthomas in CTX. Besides the classic xanthomas of the Achilles tendon (A), xanthomas of the patellar tendon (B), the extensor tendons of the hand (C), and the extensor tendons of the elbow (D) have been observed. <a href="/books/NBK1409/figure/ctx.F1/?report=objectonly" target="object" rid-ob="figobctxF1">(more...)</a></p></div></div><p><b>Brain imaging</b></p><ul><li class="half_rhythm"><div>Bilateral hyperintensity of the dentate nuclei and cerebral and cerebellar white matter (<a class="figpopup" href="/books/NBK1409/figure/ctx.F2/?report=objectonly" target="object" rid-figpopup="figctxF2" rid-ob="figobctxF2">Figure 2</a>) on brain MRI. Changes on brain CT and MRI include diffuse brain and cerebellar atrophy, white matter signal alterations, and bilateral focal cerebellar lesions [<a class="bk_pop" href="#ctx.REF.berginer.1981.1463">Berginer et al 1981</a>, <a class="bk_pop" href="#ctx.REF.waterreus.1987.169">Waterreus et al 1987</a>, <a class="bk_pop" href="#ctx.REF.berginer.1994.102">Berginer et al 1994</a>, <a class="bk_pop" href="#ctx.REF.dotti.1994.1721">Dotti et al 1994</a>, <a class="bk_pop" href="#ctx.REF.de_stefano.2001.121">De Stefano et al 2001</a>, <a class="bk_pop" href="#ctx.REF.guerrera.2010.1189">Guerrera et al 2010</a>, <a class="bk_pop" href="#ctx.REF.androdias.2012.364">Androdias et al 2012</a>, <a class="bk_pop" href="#ctx.REF.mignarri.2012a.649">Mignarri et al 2012a</a>].</div></li><li class="half_rhythm"><div>Increased brain lactate concentration (by MR spectroscopy). MR spectroscopy shows decreased n-acetylaspartate and increased lactate indicative of widespread brain mitochondrial dysfunction [<a class="bk_pop" href="#ctx.REF.de_stefano.2001.121">De Stefano et al 2001</a>].</div></li></ul><div class="iconblock whole_rhythm clearfix ten_col fig" id="figctxF2" co-legend-rid="figlgndctxF2"><a href="/books/NBK1409/figure/ctx.F2/?report=objectonly" target="object" title="Figure 2. " class="img_link icnblk_img figpopup" rid-figpopup="figctxF2" rid-ob="figobctxF2"><img class="small-thumb" src="/books/NBK1409/bin/ctx-Image002.gif" src-large="/books/NBK1409/bin/ctx-Image002.jpg" alt="Figure 2. " /></a><div class="icnblk_cntnt" id="figlgndctxF2"><h4 id="ctx.F2"><a href="/books/NBK1409/figure/ctx.F2/?report=objectonly" target="object" rid-ob="figobctxF2">Figure 2. </a></h4><p class="float-caption no_bottom_margin">MRI findings in three persons with CTX A. Signal alterations of cerebral peduncle</p></div></div><p><b>Laboratory findings.</b> CTX is caused by deficiency of the mitochondrial enzyme sterol 27-hydroxylase with resulting cholestanol and cholesterol accumulation in virtually every tissue. Note: <a class="bk_pop" href="#ctx.REF.cali.1991.7779">Cali et al [1991]</a> reported that the sterol 27-hydroxylase was often referred to in the literature as a sterol 26-hydroxylase; however, in accordance with IUPAC sterol nomenclature and the stereochemistry of the initial reaction catalyzed by this enzyme, the authors of this <i>GeneReview</i> will refer to it as sterol 27- hydroxylase. Laboratory findings include the following:</p><ul><li class="half_rhythm"><div><b>High</b> plasma and tissue <b>cholestanol</b> concentration (<a class="figpopup" href="/books/NBK1409/table/ctx.T.biochemical_abnormalities_in_cereb/?report=objectonly" target="object" rid-figpopup="figctxTbiochemicalabnormalitiesincereb" rid-ob="figobctxTbiochemicalabnormalitiesincereb">Table 1</a>).</div></li><li class="half_rhythm"><div>Normal to low plasma cholesterol concentration</div></li><li class="half_rhythm"><div>Markedly <b>decreased</b> formation of <b>chenodeoxycholic acid</b> resulting from impaired primary bile acid synthesis</div></li><li class="half_rhythm"><div><b>Increased concentration of bile alcohols</b> and their glyconjugates in bile, urine, and plasma (<a class="figpopup" href="/books/NBK1409/table/ctx.T.biochemical_abnormalities_in_cereb/?report=objectonly" target="object" rid-figpopup="figctxTbiochemicalabnormalitiesincereb" rid-ob="figobctxTbiochemicalabnormalitiesincereb">Table 1</a>)</div></li><li class="half_rhythm"><div>Increased concentration of cholestanol and apolipoprotein B in cerebrospinal fluid (CSF) resulting from <b>changes in the blood-brain barrier</b></div></li><li class="half_rhythm"><div><b>Increased</b> plasma <b>lactate</b> concentration</div></li></ul><div id="ctx.T.biochemical_abnormalities_in_cereb" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Biochemical Abnormalities in Cerebrotendinous Xanthomatosis (CTX)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1409/table/ctx.T.biochemical_abnormalities_in_cereb/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ctx.T.biochemical_abnormalities_in_cereb_lrgtbl__"><table><thead><tr><th id="hd_h_ctx.T.biochemical_abnormalities_in_cereb_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_ctx.T.biochemical_abnormalities_in_cereb_1_1_1_1" style="text-align:left;vertical-align:middle;">Analyte</th><th id="hd_h_ctx.T.biochemical_abnormalities_in_cereb_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_ctx.T.biochemical_abnormalities_in_cereb_1_1_1_2" style="text-align:left;vertical-align:middle;">Source</th><th id="hd_h_ctx.T.biochemical_abnormalities_in_cereb_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Concentration</th></tr><tr><th headers="hd_h_ctx.T.biochemical_abnormalities_in_cereb_1_1_1_3" id="hd_h_ctx.T.biochemical_abnormalities_in_cereb_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">In CTX</th><th headers="hd_h_ctx.T.biochemical_abnormalities_in_cereb_1_1_1_3" id="hd_h_ctx.T.biochemical_abnormalities_in_cereb_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</th></tr></thead><tbody><tr><td headers="hd_h_ctx.T.biochemical_abnormalities_in_cereb_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cholestanol</td><td headers="hd_h_ctx.T.biochemical_abnormalities_in_cereb_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Plasma</td><td headers="hd_h_ctx.T.biochemical_abnormalities_in_cereb_1_1_1_3 hd_h_ctx.T.biochemical_abnormalities_in_cereb_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02264;5-10x normal</td><td headers="hd_h_ctx.T.biochemical_abnormalities_in_cereb_1_1_1_3 hd_h_ctx.T.biochemical_abnormalities_in_cereb_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">330&#x000b1;30 &#x000b5;g/dL</td></tr><tr><td headers="hd_h_ctx.T.biochemical_abnormalities_in_cereb_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Bile alcohols</td><td headers="hd_h_ctx.T.biochemical_abnormalities_in_cereb_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Urine</td><td headers="hd_h_ctx.T.biochemical_abnormalities_in_cereb_1_1_1_3 hd_h_ctx.T.biochemical_abnormalities_in_cereb_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">14,000&#x000b1;3500 nmol/L</td><td headers="hd_h_ctx.T.biochemical_abnormalities_in_cereb_1_1_1_3 hd_h_ctx.T.biochemical_abnormalities_in_cereb_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Not detectable</td></tr><tr><td headers="hd_h_ctx.T.biochemical_abnormalities_in_cereb_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Plasma</td><td headers="hd_h_ctx.T.biochemical_abnormalities_in_cereb_1_1_1_3 hd_h_ctx.T.biochemical_abnormalities_in_cereb_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02264;500-1000x normal values</td><td headers="hd_h_ctx.T.biochemical_abnormalities_in_cereb_1_1_1_3 hd_h_ctx.T.biochemical_abnormalities_in_cereb_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8.48&#x000b1;3.67</td></tr></tbody></table></div></div></div><div id="ctx.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of CTX <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the clinical and biochemical testing findings above and/or by the identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>CYP27A1</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1409/table/ctx.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figctxTmoleculargenetictestingusedin" rid-ob="figobctxTmoleculargenetictestingusedin">Table 2</a>).</p><p>Molecular testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> or use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>CYP27A1</i> is performed first followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>CYP27A1</i> and other genes of interest (see <a href="#ctx.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><div id="ctx.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Cerebrotendinous Xanthomatosis</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1409/table/ctx.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ctx.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_ctx.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_ctx.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_ctx.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_ctx.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>CYP27A1</i></td><td headers="hd_h_ctx.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_ctx.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;90%</td></tr><tr><td headers="hd_h_ctx.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>4</sup></td><td headers="hd_h_ctx.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;8%&#x000a0;<sup>5</sup></td></tr><tr><td headers="hd_h_ctx.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>6</sup></td><td headers="hd_h_ctx.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_ctx.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="ctx.TF.2.1"><p class="no_margin">See <a href="/books/NBK1409/#ctx.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="ctx.TF.2.2"><p class="no_margin">See <a href="#ctx.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="ctx.TF.2.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected (see <a href="/books/NBK1409/bin/ctx-Table3.pdf">Table 3</a> [pdf]). For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="ctx.TF.2.4"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>5. </dt><dd><div id="ctx.TF.2.5"><p class="no_margin">In 55 Italian cases [Author, personal observation]</p></div></dd><dt>6. </dt><dd><div id="ctx.TF.2.6"><p class="no_margin"><a class="bk_pop" href="#ctx.REF.hansson.2007.504">Hansson et al [2007]</a> described an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual with two pathogenic variants in <a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> configuration on one <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> of <i>CYP27A1</i>; the authors postulated that a second <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in another, as-yet-unknown <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> that is critical for the activity of sterol 27-hydroxylase may be cause of the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p></div></dd></dl></div></div></div></div></div><div id="ctx.Clinical_Characteristics"><h2 id="_ctx_Clinical_Characteristics_">Clinical Characteristics</h2><div id="ctx.Clinical_Description"><h3>Clinical Description</h3><p>Cerebrotendinous xanthomatosis (CTX) is a lipid storage disease characterized by infantile-onset diarrhea, childhood-onset cataract, adolescent- to young adult-onset tendon xanthomas, and adult-onset progressive neurologic dysfunction (dementia, psychiatric disturbances, pyramidal and/or cerebellar signs, dystonia, atypical parkinsonism, peripheral neuropathy, and seizures). The clinical features of 55 individuals with CTX were reported as follows: cataracts in 49 (89%), tendon xanthomas in 43 (78%), osteoporosis in 20/30 (67%), and diarrhea in 22 (40%). Neurologic involvement included intellectual disability in 33 (60%) and psychiatric disturbances in 24 (44%). Ataxia was observed in 20 (36%), paraparesis in 35 (64%), parkinsonism in five (9%) and peripheral neuropathy in 21/30 (70%). Seizures were observed in 18 (33%) (see <a class="figpopup" href="/books/NBK1409/figure/ctx.F3/?report=objectonly" target="object" rid-figpopup="figctxF3" rid-ob="figobctxF3">Figure 3</a>). Intrafamilial variability is considerable [<a class="bk_pop" href="#ctx.REF.dotti.1996.12">Dotti et al 1996</a>, <a class="bk_pop" href="#ctx.REF.nagai.1996.571">Nagai et al 1996</a>, <a class="bk_pop" href="#ctx.REF.verrips.2000a.908">Verrips et al 2000a</a>, <a class="bk_pop" href="#ctx.REF.federico.2003.633">Federico &#x00026; Dotti 2003</a>, <a class="bk_pop" href="#ctx.REF.moghadasian.2004.42">Moghadasian 2004</a>, <a class="bk_pop" href="#ctx.REF.mignarri.2014.421">Mignarri et al 2014</a>].</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figctxF3" co-legend-rid="figlgndctxF3"><a href="/books/NBK1409/figure/ctx.F3/?report=objectonly" target="object" title="Figure 3. " class="img_link icnblk_img figpopup" rid-figpopup="figctxF3" rid-ob="figobctxF3"><img class="small-thumb" src="/books/NBK1409/bin/ctx-Image003.gif" src-large="/books/NBK1409/bin/ctx-Image003.jpg" alt="Figure 3. . Clinical features of 55 individuals with CTX (27 males, 28 females) [Mignarri et al 2014]; * refers to features that were assessed in only a subset of the 55 individuals (i." /></a><div class="icnblk_cntnt" id="figlgndctxF3"><h4 id="ctx.F3"><a href="/books/NBK1409/figure/ctx.F3/?report=objectonly" target="object" rid-ob="figobctxF3">Figure 3. </a></h4><p class="float-caption no_bottom_margin">Clinical features of 55 individuals with CTX (27 males, 28 females) [Mignarri et al 2014]; * refers to features that were assessed in only a subset of the 55 individuals (i.e., osteoporosis was seen in 20/30 affected individuals). </p></div></div><p>A distinction can be made between <a href="#ctx.Systemic_Signs">systemic signs</a> and <a href="#ctx.Neurologic_Signs">neurologic signs</a>, described in detail below.</p><div id="ctx.Systemic_Signs"><h4>Systemic Signs</h4><p><b>Enterohepatic system.</b> Chronic diarrhea from infancy may be the earliest clinical manifestation of CTX [<a class="bk_pop" href="#ctx.REF.cruysberg.1991.606">Cruysberg et al 1991</a>, <a class="bk_pop" href="#ctx.REF.cruysberg.2002.1975">Cruysberg 2002</a>]. Gallstones have been reported on occasion.</p><p><b>Eye.</b> In approximately 75% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, cataracts are the first finding, often appearing in the first decade of life. In 25% of individuals, cataracts are first observed after age 40 years. Cataracts may be visually significant opacities requiring lensectomy or visually insignificant cortical opacities. The appearance can include irregular cortical opacities, anterior polar cataracts, and dense posterior subcapsular cataracts [<a class="bk_pop" href="#ctx.REF.cruysberg.1995.597">Cruysberg et al 1995</a>].</p><p>Other findings include palpebral xanthelasmas [<a class="bk_pop" href="#ctx.REF.van_bogaert.1937">Van Bogaert et al 1937</a>, <a class="bk_pop" href="#ctx.REF.philippart.1969.603">Philippart &#x00026; Van Bogaert 1969</a>], optic nerve atrophy [<a class="bk_pop" href="#ctx.REF.schimschock.1968.688">Schimschock et al 1968</a>], and proptosis [<a class="bk_pop" href="#ctx.REF.morgan.1989.1011">Morgan et al 1989</a>]. In 13 individuals reported by <a class="bk_pop" href="#ctx.REF.dotti.2001.696">Dotti et al [2001]</a> ranging in age from 32 to 54 years, all had cataracts, approximately 50% had optic disk paleness, 30% had signs of premature retinal senescence with retinal vessel sclerosis, 15% had cholesterol-like deposits along vascular arcades, and 15% had myelinated nerve fibers.</p><p><a class="bk_pop" href="#ctx.REF.khan.2013.956">Khan et al [2013]</a> reported the unique finding of fleck lenticular opacities in three children with CTX; these <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children also had capsular opacities (posterior only or posterior and anterior) that caused visual symptoms.</p><p><b>Xanthomas</b> appear in the second or third decade. In addition to the classic xanthomas of the Achilles tendon, xanthomas also occur on the extensor tendons of the elbow and hand, the patellar tendon (<a class="figpopup" href="/books/NBK1409/figure/ctx.F1/?report=objectonly" target="object" rid-figpopup="figctxF1" rid-ob="figobctxF1">Figure 1</a>), and the neck tendons. Xanthomas have been reported in the lung, bones, and central nervous system (CNS) [<a class="bk_pop" href="#ctx.REF.brienza.2015.981">Brienza et al 2015</a>].</p><p><b>Cardiovascular system.</b> Premature atherosclerosis and coronary artery disease have been reported [<a class="bk_pop" href="#ctx.REF.schimschock.1968.688">Schimschock et al 1968</a>, <a class="bk_pop" href="#ctx.REF.fujiyama.1991.1">Fujiyama et al 1991</a>, <a class="bk_pop" href="#ctx.REF.kerleau.1993.1460">Kerleau et al 1993</a>, <a class="bk_pop" href="#ctx.REF.valdivielso.2004.680">Valdivielso et al 2004</a>, <a class="bk_pop" href="#ctx.REF.frihayed.2005.992">Frih-Ayed et al 2005</a>], as has lipomatous hypertrophy of the atrial septum [<a class="bk_pop" href="#ctx.REF.dotti.1998.723">Dotti et al 1998</a>]. The increased prevalence of atherosclerosis in individuals with CTX can be partially explained by the following mechanisms: alteration of the plasma lipid and lipoprotein profile; alteration of bile alcohols; lack of sterol 27-hydroxylase activity in the cellular constituents of the atheroma; and absence of a defense mechanism for macrophages in the metabolism of cholesterol into 27-hydroxycholesterol and 3p-hydroxy5-cholestanoic acid [<a class="bk_pop" href="#ctx.REF.leitersdorf.1994.907">Leitersdorf et al 1994</a>].</p><p><b>Skeleton.</b> Bone involvement is characterized by granulomatous lesions in the lumbar vertebrae and femur, osteopenia and increased risk of bone fractures, and impaired adsorption of radiocalcium, which improves with chenodeoxycholic acid treatment [<a class="bk_pop" href="#ctx.REF.berginer.1993.69">Berginer et al 1993</a>, <a class="bk_pop" href="#ctx.REF.federico.1993.67">Federico et al 1993</a>, <a class="bk_pop" href="#ctx.REF.martini.2013.282">Martini et al 2013</a>]. Osteopenia is evident by total body densitometry in untreated individuals. Individuals may have marked thoracic kyphosis.</p><p><b>Endocrine abnormalities.</b> Hypothyroidism has occasionally been reported [<a class="bk_pop" href="#ctx.REF.philippart.1969.603">Philippart &#x00026; Van Bogaert 1969</a>, <a class="bk_pop" href="#ctx.REF.bouwes_bavinck.1986.1269">Bouwes Bavinck et al 1986</a>, <a class="bk_pop" href="#ctx.REF.idouji.1991.402">Idouji et al 1991</a>].</p><p><b>Premature aging.</b> Early-onset cataract, osteopenia with bone fractures and loss of teeth, atherosclerosis, and neurologic impairment with dementia and/or parkinsonism, associated with the characteristic facies, suggest a generalized premature aging process [<a class="bk_pop" href="#ctx.REF.dotti.1991.371">Dotti et al 1991</a>].</p></div><div id="ctx.Neurologic_Signs"><h4>Neurologic Signs</h4><p><b>Intellectual disability or dementia</b> following slow deterioration in intellectual abilities occurs in the 20s in more than 50% of individuals [<a class="bk_pop" href="#ctx.REF.verrips.2000b.407">Verrips et al 2000b</a>]. Some individuals show cognitive impairment from early infancy, whereas the majority have normal or only slightly impaired intellectual function until puberty. In the spinal form, mainly characterized by myelopathy and spastic paraparesis, intellect is almost always normal.</p><p><b>Neuropsychiatric symptoms</b> including behavioral changes, hallucinations, agitation, aggression, depression, and suicide attempts may be prominent.</p><p><b>Pyramidal signs (i.e., spasticity) and/or cerebellar signs</b> are almost invariably present between ages 20 and 30 years. A spinal form, in which spastic paraparesis is the main clinical symptom, was described by <a class="bk_pop" href="#ctx.REF.van_bogaert.1962.433">Van Bogaert [1962]</a> and more recently by <a class="bk_pop" href="#ctx.REF.verrips.1999a.1589">Verrips et al [1999a]</a> and <a class="bk_pop" href="#ctx.REF.mignarri.2011.783">Mignarri et al [2011]</a>.</p><p><b>Extrapyramidal manifestations</b> including dystonia and atypical parkinsonism have been reported on occasion [<a class="bk_pop" href="#ctx.REF.fiorelli.1990.76">Fiorelli et al 1990</a>, <a class="bk_pop" href="#ctx.REF.rogelet.1992.541">Rogelet et al 1992</a>, <a class="bk_pop" href="#ctx.REF.dotti.2000.1017">Dotti et al 2000</a>, <a class="bk_pop" href="#ctx.REF.grandas.2002.1396">Grandas et al 2002</a>, <a class="bk_pop" href="#ctx.REF.mignarri.2012b.99">Mignarri et al 2012b</a>]. Although palatal myoclonus was observed in the first individual reported [<a class="bk_pop" href="#ctx.REF.van_bogaert.1937">Van Bogaert et al 1937</a>], it was not observed in a large series of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#ctx.REF.dotti.2001.696">Dotti et al 2001</a>].</p><p><b>Seizures</b> are reported in approximately 50% of individuals with CTX [<a class="bk_pop" href="#ctx.REF.matsumuro.1990.207">Matsumuro et al 1990</a>, <a class="bk_pop" href="#ctx.REF.arlazoroff.1991.657">Arlazoroff et al 1991</a>, <a class="bk_pop" href="#ctx.REF.dotti.1996.12">Dotti et al 1996</a>].</p><p><b>Peripheral neuropathy</b> is evident on electrophysiologic studies [<a class="bk_pop" href="#ctx.REF.ohnishi.1979.43">Ohnishi et al 1979</a>, <a class="bk_pop" href="#ctx.REF.argov.1986.89">Argov et al 1986</a>, <a class="bk_pop" href="#ctx.REF.federico.1987.360">Federico et al 1987</a>, <a class="bk_pop" href="#ctx.REF.ben_hamida.1991.385">Ben Hamida et al 1991</a>, <a class="bk_pop" href="#ctx.REF.ginanneschi.2013.268">Ginanneschi et al 2013</a>], which reveal decreased nerve conduction velocities (NCV) and abnormalities in somatosensory, motor, brain stem, and visual evoked potentials. Clinical manifestations related to peripheral nerve involvement are distal muscle atrophy and pes cavus. Sensory abnormalities are rarely described.</p></div><div id="ctx.Neuroimaging"><h4>Neuroimaging</h4><p>The quantitative assessment of brain damage in CTX with use of magnetization transfer MRI has also been described [<a class="bk_pop" href="#ctx.REF.inglese.2003.495">Inglese et al 2003</a>].</p></div><div id="ctx.Pathology_Findings"><h4>Pathology Findings</h4><p><b>Histologic changes.</b> Histologic liver findings include electron-dense amorphous material surrounded by smooth endoplasmic reticulum [<a class="bk_pop" href="#ctx.REF.salen.1978.82">Salen et al 1978</a>] and abnormalities in mitochondria with paracrystalline inclusions and increased number of peroxisomes [<a class="bk_pop" href="#ctx.REF.federico.1989">Federico 1989</a>]. Xanthomas are characterized by birefringent crystalline material surrounded by numerous multinucleate giant cells with foamy cytoplasm.</p><p><b>Neuropathology.</b> Classic CNS pathology findings in CTX include granulomatous and xanthomatous lesions in the cerebellar hemispheres, globus pallidus, and cerebellar peduncles. Demyelination and gliosis and involvement of the long tract of the spinal cord have been described [<a class="bk_pop" href="#ctx.REF.van_bogaert.1937">Van Bogaert et al 1937</a>, <a class="bk_pop" href="#ctx.REF.van_bogaert.1962.433">Van Bogaert 1962</a>]. Nerve biopsy reveals primary axonal degeneration, demyelination, and remyelination. <a class="bk_pop" href="#ctx.REF.federico.1991.734">Federico et al [1991]</a> found mild myopathic changes of increased variability of fiber size with randomly distributed atrophic fibers. Ultrastructural abnormalities included mitochondrial subsarcolemmal aggregates and morphologic changes of these organelles [<a class="bk_pop" href="#ctx.REF.federico.1991.734">Federico et al 1991</a>]. Reduced respiratory chain enzyme activity has been observed [<a class="bk_pop" href="#ctx.REF.dotti.1995.106">Dotti et al 1995</a>].</p></div><div id="ctx.Heterozygotes"><h4>Heterozygotes</h4><p>Heterozygotes are generally asymptomatic; however, clinical findings have been reported in heterozygotes ranging from an increased incidence of cardiovascular disorders and gall stones to a symptomatic <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a> with biochemically proven CTX [<a class="bk_pop" href="#ctx.REF.sugama.2001.379">Sugama et al 2001</a>; Author, personal observation]. <a class="bk_pop" href="#ctx.REF.hansson.2007.504">Hansson et al [2007]</a> described an individual with CTX with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>CYP27A1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and a presumed second pathogenic variant in an undefined <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> that possibly encodes a protein responsible for transport of cholesterol into the mitochondria.</p></div></div><div id="ctx.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>No <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> have been identified [<a class="bk_pop" href="#ctx.REF.dotti.1996.12">Dotti et al 1996</a>, <a class="bk_pop" href="#ctx.REF.verrips.2000c.520">Verrips et al 2000c</a>]. The interaction of many genes and other factors may influence the clinical presentation.</p></div><div id="ctx.Nomenclature"><h3>Nomenclature</h3><p>Terms used in the past for cerebrotendinous xanthomatosis and no longer in use include the following:</p><ul><li class="half_rhythm"><div>Cerebral cholesterinosis</div></li><li class="half_rhythm"><div>Cerebrotendinous cholesterosis</div></li><li class="half_rhythm"><div>Van Bogaert-Scherer-Epstein syndrome</div></li></ul></div><div id="ctx.Prevalence"><h3>Prevalence</h3><p>The prevalence of CTX is estimated at 0.13:100,000 individuals (see <a href="http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Orphanet: Prevalence and incidence of rare diseases: Bibilographic data</a> [pdf]).</p><p>The prevalence of CTX caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> (<a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a>) p.Arg395Cys pathogenic variants has been estimated at 1:50,000 among persons of northern European heritage [<a class="bk_pop" href="#ctx.REF.lorincz.2005.1459">Lorincz et al 2005</a>].</p><p>Series of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have been reported in Israel and the US [<a class="bk_pop" href="#ctx.REF.berginer.1984.1649">Berginer et al 1984</a>], Italy [<a class="bk_pop" href="#ctx.REF.de_stefano.2001.121">De Stefano et al 2001</a>, <a class="bk_pop" href="#ctx.REF.dotti.2001.696">Dotti et al 2001</a>], Spain [<a class="bk_pop" href="#ctx.REF.pilodelafuente.2011.1203">Pilo-de-la-Fuente et al 2011</a>], Japan [<a class="bk_pop" href="#ctx.REF.kuriyama.1991.225">Kuriyama et al 1991</a>], and the Netherlands [<a class="bk_pop" href="#ctx.REF.waterreus.1987.169">Waterreus et al 1987</a>, <a class="bk_pop" href="#ctx.REF.verrips.2000a.908">Verrips et al 2000a</a>]. Affected individuals have been reported in Belgium [<a class="bk_pop" href="#ctx.REF.van_bogaert.1937">Van Bogaert et al 1937</a>, <a class="bk_pop" href="#ctx.REF.philippart.1969.603">Philippart &#x00026; Van Bogaert 1969</a>], Brazil [<a class="bk_pop" href="#ctx.REF.canelas.1983.305">Canelas et al 1983</a>], Canada [<a class="bk_pop" href="#ctx.REF.pastershank.1974.282">Pastershank et al 1974</a>], France [<a class="bk_pop" href="#ctx.REF.rogelet.1992.541">Rogelet et al 1992</a>], Iran [<a class="bk_pop" href="#ctx.REF.farpour.1975.223">Farpour &#x00026; Mahloudji 1975</a>], Norway [<a class="bk_pop" href="#ctx.REF.schreiner.1975.405">Schreiner et al 1975</a>], Tunisia [<a class="bk_pop" href="#ctx.REF.ben_hamida.1991.385">Ben Hamida et al 1991</a>], Spain [<a class="bk_pop" href="#ctx.REF.campdelacreu.2002.647">Campdelacreu et al 2002</a>], China [<a class="bk_pop" href="#ctx.REF.ko.2001.30">Ko &#x00026; Lee 2001</a>], and Sweden [<a class="bk_pop" href="#ctx.REF.rystedt.2002.259">Rystedt et al 2002</a>].</p></div></div><div id="ctx.Genetically_Related_Allelic_Disorder"><h2 id="_ctx_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>CYP27A1</i>.</p></div><div id="ctx.Differential_Diagnosis"><h2 id="_ctx_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>Xanthomas.</b> Differential diagnosis includes the following:</p><ul><li class="half_rhythm"><div><a href="/books/n/gene/stsl/">Sitosterolemia</a>, inherited sterol storage disease characterized by tendon or tuberous xanthomas, a strong predisposition to premature atherosclerosis, and abnormal hematologic findings. Serum concentration of plant sterols (sitosterol and campesterol) is increased. Primary neurologic signs and cataracts are not present. Spastic paraparesis may occur as a result of spinal cord compression by multiple intradural, extramedullary xanthomas [<a class="bk_pop" href="#ctx.REF.hatanaka.1990.390">Hatanaka et al 1990</a>]. Sitosterolemia is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner and caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in either <i>ABCG5</i> or <i>ABCG8</i>.</div></li><li class="half_rhythm"><div>Hypercholesterolemia and hyperlipemia (especially type IIa), in which plasma cholestanol level is normal. See <a href="/books/n/gene/hyperchol/">Familial Hypercholesterolemia</a>.</div></li></ul><p>When xanthomas are not evident, the differential diagnosis of cerebrotendinous xanthomatosis (CTX), includes all forms of progressive mental deterioration [<a class="bk_pop" href="#ctx.REF.gilad.1999.405">Gilad et al 1999</a>, <a class="bk_pop" href="#ctx.REF.verrips.2000b.407">Verrips et al 2000b</a>].</p><p><b>Early-onset cataract.</b>
<a class="bk_pop" href="#ctx.REF.cruysberg.2002.1975">Cruysberg [2002]</a> reported that individuals with CTX comprise the second-largest group with early-onset cataract and known neurologic disease. (<a href="/books/n/gene/myotonic-d/">Myotonic dystrophy type 1</a> is the largest group.) Unexplained juvenile-onset cataracts associated with infantile-onset chronic diarrhea and intellectual disability or deterioration strongly suggest the possibility of CTX [<a class="bk_pop" href="#ctx.REF.cruysberg.1991.606">Cruysberg et al 1991</a>, <a class="bk_pop" href="#ctx.REF.cruysberg.1995.597">Cruysberg et al 1995</a>, <a class="bk_pop" href="#ctx.REF.verrips.2000b.407">Verrips et al 2000b</a>].</p></div><div id="ctx.Management"><h2 id="_ctx_Management_">Management</h2><div id="ctx.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with cerebrotendinous xanthomatosis, the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>EMG and nerve conduction velocity in order to evaluate for peripheral neuropathy</div></li><li class="half_rhythm"><div>Cardiologic evaluation including EKG and echocardiogram</div></li><li class="half_rhythm"><div>Laboratory investigations of lipids including measurement of plasma cholestanol level (if not performed as part of the diagnostic evaluation)</div></li><li class="half_rhythm"><div>Evaluation for osteoporosis</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="ctx.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p><b>Chenodeoxycholic acid (CDCA).</b> Long-term treatment with CDCA (750 mg/day in adults) normalizes bile acid synthesis (leading to disappearance of abnormal metabolites from serum, bile, and urine), normalizes plasma and CSF concentration of cholestanol by suppressing cholestanol biosynthesis, and improves neurophysiologic findings [<a class="bk_pop" href="#ctx.REF.mondelli.1992.469">Mondelli et al 1992</a>, <a class="bk_pop" href="#ctx.REF.mondelli.2001.29">Mondelli et al 2001</a>] and other clinical manifestations including osteoporosis [<a class="bk_pop" href="#ctx.REF.federico.1993.67">Federico et al 1993</a>]. For recent reports see: <a class="bk_pop" href="#ctx.REF.bonnot.2010.231">Bonnot et al [2010]</a>, <a class="bk_pop" href="#ctx.REF.ginanneschi.2013.268">Ginanneschi et al [2013]</a>, <a class="bk_pop" href="#ctx.REF.martini.2013.282">Martini et al [2013]</a>, and <a class="bk_pop" href="#ctx.REF.yahalom.2013.78">Yahalom et al [2013]</a>.</p><p>Treatment with CDCA has been reported to lead to the following [<a class="bk_pop" href="#ctx.REF.mondelli.2001.29">Mondelli et al 2001</a>]:</p><ul><li class="half_rhythm"><div>Normalization of nerve conduction velocities and subsequent stabilization</div></li><li class="half_rhythm"><div>Slow and continuous improvement in motor evoked potentials (MEPs) and sensory evoked potentials (SEPs)</div></li><li class="half_rhythm"><div>Overall stabilization of clinical manifestations without significant improvement of neurologic deficits.</div><ul><li class="half_rhythm"><div>In peripheral nerves CDCA treatment did not influence the number of axons activated by maximum electrical stimulation but instead it increased the conduction of the still-excitable fibers. This suggests that CDCA treatment promotes myelin synthesis in nerve fibers with residual unaffected axons.</div></li><li class="half_rhythm"><div>The effect of therapy may therefore depend largely on the extent of irreversible structural damage to axons.</div></li><li class="half_rhythm"><div>CDCA treatment may be more useful when started early. In a case in which treatment onset was at birth the development of disease appears to be delayed [Authors, personal data; <a class="bk_pop" href="#ctx.REF.luyckx.2014.9">Luyckx et al 2014</a>].</div></li></ul></li></ul><p><b>Inhibitors of HMG-CoA reductase</b> alone or in combination with CDCA are also effective in decreasing cholestanol concentration and improving clinical signs [<a class="bk_pop" href="#ctx.REF.peynet.1991.434">Peynet et al 1991</a>, <a class="bk_pop" href="#ctx.REF.verrips.1999b.233">Verrips et al 1999b</a>]. However, because of clinical evidence that HMG-CoA reductase inhibitors may induce muscle damage and even rhabdomyolysis, caution is required in the use of these drugs [<a class="bk_pop" href="#ctx.REF.federico.1994.2218">Federico &#x00026; Dotti 1994</a>].</p><p><b>Low-density lipoprotein (LDL) apheresis</b> has been proposed as a possible treatment; results are controversial [<a class="bk_pop" href="#ctx.REF.mimura.1993.227">Mimura et al 1993</a>, <a class="bk_pop" href="#ctx.REF.berginer.1994.229">Berginer &#x00026; Salen 1994</a>, <a class="bk_pop" href="#ctx.REF.dotti.2004.185">Dotti et al 2004</a>].</p><p><b>Coenzyme Q<sub>10</sub></b> (CoQ<sub>10</sub>) treatment may improve muscle weakness.</p><p><b>Liver transplantation</b>, although never performed in individuals with CTX, remains a possibility.</p><p><b>Eyes.</b> Cataract extraction is typically required in at least one eye by age 50 years.</p><p><b>Symptomatic treatments</b> for epilepsy, spasticity, and parkinsonism have been utilized. Parkinsonism is poorly responsive to levodopa, whereas an antihistamine drug, diphenylpyraline hydrochloride, had an excellent effect in three individuals [<a class="bk_pop" href="#ctx.REF.ohno.2001.95">Ohno et al 2001</a>].</p></div><div id="ctx.Prevention_of_Primary_Manifestations"><h3>Prevention of Primary Manifestations</h3><p>Early treatment with CDCA in presymptomatic individuals appears to prevent clinical manifestations (see <a href="#ctx.Treatment_of_Manifestations">Treatment of Manifestations</a>).</p></div><div id="ctx.Prevention_of_Secondary_Complication"><h3>Prevention of Secondary Complications</h3><p>Calcium and vitamin D supplementation improve osteoporosis.</p></div><div id="ctx.Surveillance"><h3>Surveillance</h3><p>Recommended annual surveillance includes the following:</p><ul><li class="half_rhythm"><div>Neurologic and neuropsychologic evaluation</div></li><li class="half_rhythm"><div>Cholestanol plasma concentration</div></li><li class="half_rhythm"><div>Brain MRI</div></li><li class="half_rhythm"><div>Echocardiography</div></li><li class="half_rhythm"><div>Measurement of total body density (TBD)</div></li></ul></div><div id="ctx.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Caution in the use of statins has been suggested [<a class="bk_pop" href="#ctx.REF.federico.2001.1743">Federico &#x00026; Dotti 2001</a>].</p></div><div id="ctx.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to clarify the genetic status of apparently asymptomatic older and younger sibs of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of the <i>CYP27A1</i> pathogenic variants in the family in order to identify as early as possible those who would benefit from prompt initiation of treatment. If the pathogenic variants in the family are not known, biochemical testing of at-risk individuals can be pursued.</p><p>See <a href="#ctx.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="ctx.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Treatment with chenodeoxycholic acid should not be interrupted during pregnancy.</p></div><div id="ctx.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Therapies with statins and LDL apheresis have been reported [<a class="bk_pop" href="#ctx.REF.dotti.2004.185">Dotti et al 2004</a>]. Cholic acid was used to treat two <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> sibs from infancy with resulting improvement in symptoms [<a class="bk_pop" href="#ctx.REF.pierre.2008.s241">Pierre et al 2008</a>].</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div><div id="ctx.Other"><h3>Other</h3><p>Therapies with ursodeoxicolic acid, lovastatin, and cholestyramine have been reported to be ineffective [<a class="bk_pop" href="#ctx.REF.tint.1989.633">Tint et al 1989</a>, <a class="bk_pop" href="#ctx.REF.batta.2004.556">Batta et al 2004</a>].</p></div></div><div id="ctx.Genetic_Counseling"><h2 id="_ctx_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="ctx.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Cerebrotendinous xanthomatosis (CTX) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="ctx.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers of one <i>CYP27A1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are generally asymptomatic, although clinical findings have been reported in a few heterozygotes. (See <a href="#ctx.Heterozygotes">Heterozygotes</a>.)</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are generally asymptomatic. (See <a href="#ctx.Heterozygotes">Heterozygotes</a>.)</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an individual with CTX are obligate heterozygotes (carriers) for a <i>CYP27A1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <i>CYP27A1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="ctx.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>CYP27A1</i> pathogenic variants in the family.</p></div><div id="ctx.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#ctx.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="ctx.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>CYP27A1</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p></div></div><div id="ctx.Resources"><h2 id="_ctx_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>United Leukodystrophy Foundation (ULF)</b></div><div>224 North Second Street</div><div>Suite 2</div><div>DeKalb IL 60115</div><div><b>Phone:</b> 800-728-5483 (toll-free); 815-748-3211</div><div><b>Fax:</b> 815-748-0844</div><div><b>Email:</b> office@ulf.org</div><div><a href="http://www.ulf.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ulf.org</a></div></li><li class="half_rhythm"><div><b>Metabolic Support UK</b></div><div>5 Hilliards Court, Sandpiper Way</div><div>Chester Business Park</div><div>Chester CH4 9QP </div><div>United Kingdom</div><div><b>Phone:</b> 0845 241 2173</div><div><b>Email:</b> contact@metabolicsupportuk.org</div><div><a href="https://www.metabolicsupportuk.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.metabolicsupportuk.org</a></div></li><li class="half_rhythm"><div><b>National Organization for Rare Disorders (NORD)</b></div><div>RareCareSM</div><div><b>Phone:</b> 800-999-6673</div><div><a href="https://rarediseases.org/for-patients-and-families/help-access-medications/patient-assistance-programs-2/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Patient Assistance Programs</a></div></li><li class="half_rhythm"><div><b>Myelin Disorders Bioregistry Project</b></div><div><b>Email:</b> myelindisorders@cnmc.org</div><div><a href="https://www.chop.edu/research/myelin-disorders-biorepository-project" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Myelin Disorders Bioregistry Project</a></div></li><li class="half_rhythm"><div><b>RDCRN Patient Contact Registry: Sterol and Isoprenoid Research Consortium</b></div><div><a href="https://www.rarediseasesnetwork.org/cms/stair" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RDCRN Patient Contact Registry</a></div></li></ul></div><div id="ctx.Molecular_Genetics"><h2 id="_ctx_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="ctx.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Cerebrotendinous Xanthomatosis: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1409/table/ctx.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ctx.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_ctx.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_ctx.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_ctx.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_ctx.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_ctx.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_ctx.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_ctx.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/1593" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>CYP27A1</i></a></td><td headers="hd_b_ctx.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=1593" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">2q35</a></td><td headers="hd_b_ctx.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q02318" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Sterol 26-hydroxylase, mitochondrial</a></td><td headers="hd_b_ctx.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/CYP27A1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CYP27A1 @ LOVD</a></td><td headers="hd_b_ctx.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=CYP27A1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CYP27A1</a></td><td headers="hd_b_ctx.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=CYP27A1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CYP27A1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="ctx.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="ctx.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Cerebrotendinous Xanthomatosis (<a href="/omim/213700,606530" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1409/table/ctx.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__ctx.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/213700" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">213700</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CEREBROTENDINOUS XANTHOMATOSIS; CTX</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/606530" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">606530</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CYTOCHROME P450, SUBFAMILY XXVIIA, POLYPEPTIDE 1; CYP27A1</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>CYP27A1</i> has nine exons [<a class="bk_pop" href="#ctx.REF.leitersdorf.1993.2488">Leitersdorf et al 1993</a>]. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1409/#ctx.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b>
<i>CYP27A1</i> pathogenic variants have been reported by <a class="bk_pop" href="#ctx.REF.cali.1991.7779">Cali et al [1991]</a>, <a class="bk_pop" href="#ctx.REF.verrips.2000a.908">Verrips et al [2000a]</a>, and <a class="bk_pop" href="#ctx.REF.gallus.2006.143">Gallus et al [2006]</a>.</p><p>See <a href="/books/NBK1409/bin/ctx-Table3.pdf">Table 3</a> (pdf).</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The sterol 27-hydroxylase enzyme consists of 531 amino acids. Residues 1-33 encode the transit peptide that directs the protein to the mitochondrion. The mature mitocondrial peptide has 498 amino acids and contains putative binding sites for adrenodoxin and heme encoded by the region between exons 6 and 8.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Inactive truncated sterol 27-hydroxylase protein leads to several metabolic derangements including increased cholestanol production and bile alcohols [<a class="bk_pop" href="#ctx.REF.bjorkhem.1995">Bjorkhem &#x00026; Boberg 1995</a>]. Many of the reported pathogenic variants involve splice sites and are predicted to affect <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> stability or lead to the formation of abnormal mRNA with translation products that are devoid of an adrenodoxin-binding region (residues 351-356) and/or the heme-binding site (residue 453-464), important for enzyme activity. Pathogenic <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants are predicted to result in truncated peptides devoid of function. Approximately 50% of pathogenic variants are <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants that are predicted to lead to the expression of an abnormal sterol 27-hydroxylase.</p></div><div id="ctx.References"><h2 id="_ctx_References_">References</h2><div id="ctx.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.androdias.2012.364">Androdias G, Vukusic S, Gignoux L, Boespflug-Tanguy O, Acquaviva C, Zabot MT, Couvert P, Carrie A, Confavreux C, Labauge P. Leukodystrophy with a cerebellar cystic aspect and intracranial atherosclerosis: an atypical presentation of cerebrotendinous xanthomatosis. <span><span class="ref-journal">J Neurol. </span>2012;<span class="ref-vol">259</span>:364–6.</span> [<a href="/pubmed/21769531" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21769531</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.argov.1986.89">Argov Z, Soffer D, Eisenberg S, Zimmerman Y. Chronic demyelinating peripheral neuropathy in cerebrotendinous xanthomatosis. <span><span class="ref-journal">Ann Neurol. </span>1986;<span class="ref-vol">20</span>:89–91.</span> [<a href="/pubmed/3017187" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3017187</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.arlazoroff.1991.657">Arlazoroff A, Roitberg B, Werber E, Shidlo R, Berginer VM. Epileptic seizure as a presenting symptom of cerebrotendinous xanthomatosis. <span><span class="ref-journal">Epilepsia. </span>1991;<span class="ref-vol">32</span>:657–61.</span> [<a href="/pubmed/1915172" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1915172</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.batta.2004.556">Batta AK, Salen G, Tint GS. Hydrophilic 7 beta-hydroxy bile acids, lovastatin, and cholestyramine are ineffective in the treatment of cerebrotendinous xanthomatosis. <span><span class="ref-journal">Metabolism. </span>2004;<span class="ref-vol">53</span>:556–62.</span> [<a href="/pubmed/15131757" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15131757</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.ben_hamida.1991.385">Ben Hamida M, Chabbi N, Ben Hamida C, Mhiri C, Kallel R. Peripheral neuropathy in a sporadic case of cerebrotendinous xanthomatosis. <span><span class="ref-journal">Rev Neurol (Paris). </span>1991;<span class="ref-vol">147</span>:385–8.</span> [<a href="/pubmed/1649488" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1649488</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.berginer.1994.102">Berginer VM, Berginer J, Korczyn AD, Tadmor R. Magnetic resonance imaging in cerebrotendinous xanthomatosis: a prospective clinical and neuroradiological study. <span><span class="ref-journal">J Neurol Sci. </span>1994;<span class="ref-vol">122</span>:102–8.</span> [<a href="/pubmed/8195796" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8195796</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.berginer.1981.1463">Berginer VM, Berginer J, Salen G, Shefer S, Zimmerman RD. Computed tomography in cerebrotendinous xanthomatosis. <span><span class="ref-journal">Neurology. </span>1981;<span class="ref-vol">31</span>:1463–5.</span> [<a href="/pubmed/7198194" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7198194</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.berginer.1994.229">Berginer VM, Salen G. LDL-apheresis cannot be recommended for treatment of cerebrotendinous xanthomatosis. <span><span class="ref-journal">J Neurol Sci. </span>1994;<span class="ref-vol">121</span>:229–32.</span> [<a href="/pubmed/8158220" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8158220</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.berginer.1984.1649">Berginer VM, Salen G, Shefer S. Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. <span><span class="ref-journal">N Engl J Med. </span>1984;<span class="ref-vol">311</span>:1649–52.</span> [<a href="/pubmed/6504105" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6504105</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.berginer.1993.69">Berginer VM, Shany S, Alkalay D, Berginer J, Dekel S, Salen G, Tint GS, Gazit D. Osteoporosis and increased bone fractures in cerebrotendinous xanthomatosis. <span><span class="ref-journal">Metabolism. </span>1993;<span class="ref-vol">42</span>:69–74.</span> [<a href="/pubmed/8446051" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8446051</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.bjorkhem.1995">Bjorkhem I, Boberg KM. Inborn errors in bile and biosynthesis and storage of sterols other than cholesterol. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. <em>The Metabolic and Molecular Basis of Inherited Disease.</em> 7 ed. New York, NY: McGraw-Hill; 1995:2073-99.</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.bonnot.2010.231">Bonnot O, Fraidakis MJ, Lucanto R, Chauvin D, Kelley N, Plaza M, Dubourg O, Lyon-Caen O, Sedel F, Cohen D. Cerebrotendinous xanthomatosis presenting with severe externalized disorder: improvement after one year of treatment with chenodeoxycholic Acid. <span><span class="ref-journal">CNS Spectr. </span>2010;<span class="ref-vol">15</span>:231–6.</span> [<a href="/pubmed/20414172" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20414172</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.bouwes_bavinck.1986.1269">Bouwes Bavinck JN, Vermeer BJ, Gevers Leuven JA, Koopman BJ, Wolthers BG. Capillary gas chromatography of urine samples in diagnosing cerebrotendinous xanthomatosis. <span><span class="ref-journal">Arch Dermatol. </span>1986;<span class="ref-vol">122</span>:1269–72.</span> [<a href="/pubmed/3777973" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3777973</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.brienza.2015.981">Brienza M, Fiermonte G, Cambieri C, Mignarri A, Dotti MT, Fiorelli M. Enlarging brain xanthomas in a patient with cerebrotendinous xanthomatosis. <span><span class="ref-journal">J Inherit Metab Dis. </span>2015;<span class="ref-vol">38</span>:981–2.</span> [<a href="/pubmed/25567502" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25567502</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.cali.1991.7779">Cali JJ, Hsieh CL, Francke U, Russell DW. Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. <span><span class="ref-journal">J Biol Chem. </span>1991;<span class="ref-vol">266</span>:7779–83.</span> [<a href="/pmc/articles/PMC4449724/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4449724</span></a>] [<a href="/pubmed/2019602" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2019602</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.campdelacreu.2002.647">Campdelacreu J, Munoz E, Cervera A, Jauma S, Giros M, Tolosa E. Cerebrotendinous xanthomatosis without tendinous xanthomas: presentation of two cases. <span><span class="ref-journal">Neurologia. </span>2002;<span class="ref-vol">17</span>:647–50.</span> [<a href="/pubmed/12487962" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12487962</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.canelas.1983.305">Canelas HM, Quintao EC, Scaff M, Vasconcelos KS, Brotto MW. Cerebrotendinous xanthomatosis: clinical and laboratory study of 2 cases. <span><span class="ref-journal">Acta Neurol Scand. </span>1983;<span class="ref-vol">67</span>:305–11.</span> [<a href="/pubmed/6410671" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6410671</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.cruysberg.2002.1975">Cruysberg JR. Cerebrotendinous xanthomatosis: juvenile cataract and chronic diarrhea before the onset of neurologic disease. <span><span class="ref-journal">Arch Neurol. </span>2002;<span class="ref-vol">59</span>:1975.</span> [<a href="/pubmed/12470193" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12470193</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.cruysberg.1991.606">Cruysberg JR, Wevers RA, Tolboom JJ. Juvenile cataract associated with chronic diarrhea in pediatric cerebrotendinous xanthomatosis. <span><span class="ref-journal">Am J Ophthalmol. </span>1991;<span class="ref-vol">112</span>:606–7.</span> [<a href="/pubmed/1951610" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1951610</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.cruysberg.1995.597">Cruysberg JR, Wevers RA, van Engelen BG, Pinckers A, van Spreeken A, Tolboom JJ. Ocular and systemic manifestations of cerebrotendinous xanthomatosis. <span><span class="ref-journal">Am J Ophthalmol. </span>1995;<span class="ref-vol">120</span>:597–604.</span> [<a href="/pubmed/7485361" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7485361</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.de_stefano.2001.121">De Stefano N, Dotti MT, Mortilla M, Federico A. Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis. <span><span class="ref-journal">Brain. </span>2001;<span class="ref-vol">124</span>:121–31.</span> [<a href="/pubmed/11133792" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11133792</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.dotti.2000.1017">Dotti MT, Federico A, Garuti R, Calandra S. Cerebrotendinous xanthomatosis with predominant parkinsonian syndrome: further confirmation of the clinical heterogeneity. <span><span class="ref-journal">Mov Disord. </span>2000;<span class="ref-vol">15</span>:1017–9.</span> [<a href="/pubmed/11009219" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11009219</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.dotti.1994.1721">Dotti MT, Federico A, Signorini E, Caputo N, Venturi C, Filosomi G, Guazzi GC. Cerebrotendinous xanthomatosis (van Bogaert-Scherer-Epstein disease): CT and MR findings. <span><span class="ref-journal">AJNR Am J Neuroradiol. </span>1994;<span class="ref-vol">15</span>:1721–6.</span> [<a href="/pubmed/7847220" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7847220</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.dotti.1996.12">Dotti MT, Garuti R, Calandra S, Federico A. Clinical and genetic variability of CTX. <span><span class="ref-journal">Eur J Neurol. </span>1996;<span class="ref-vol">3</span> Suppl 5:12.</span> (Abstract)</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.dotti.2004.185">Dotti MT, Lutjohann D, von Bergmann K, Federico A. Normalisation of serum cholestanol concentration in a patient with cerebrotendinous xanthomatosis by combined treatment with chenodeoxycholic acid, simvastatin and LDL apheresis. <span><span class="ref-journal">Neurol Sci. </span>2004;<span class="ref-vol">25</span>:185–91.</span> [<a href="/pubmed/15549503" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15549503</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.dotti.1995.106">Dotti MT, Manneschi L, Federico A. Mitochondrial enzyme deficiency in cerebrotendinous xanthomatosis. <span><span class="ref-journal">J Neurol Sci. </span>1995;<span class="ref-vol">129</span>:106–8.</span> [<a href="/pubmed/7608723" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7608723</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.dotti.1998.723">Dotti MT, Mondillo S, Plewnia K, Agricola E, Federico A. Cerebrotendinous xanthomatosis: evidence of lipomatous hypertrophy of the atrial septum. <span><span class="ref-journal">J Neurol. </span>1998;<span class="ref-vol">245</span>:723–6.</span> [<a href="/pubmed/9808240" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9808240</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.dotti.2001.696">Dotti MT, Rufa A, Federico A. Cerebrotendinous xanthomatosis: heterogeneity of clinical phenotype with evidence of previously undescribed ophthalmological findings. <span><span class="ref-journal">J Inherit Metab Dis. </span>2001;<span class="ref-vol">24</span>:696–706.</span> [<a href="/pubmed/11804206" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11804206</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.dotti.1991.371">Dotti MT, Salen G, Federico A. Cerebrotendinous xanthomatosis as a multisystem disease mimicking premature ageing. <span><span class="ref-journal">Dev Neurosci. </span>1991;<span class="ref-vol">13</span>:371–6.</span> [<a href="/pubmed/1817044" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1817044</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.farpour.1975.223">Farpour H, Mahloudji M. Familial cerebrotendinous xanthomatosis. Report of a new family and review of the literature. <span><span class="ref-journal">Arch Neurol. </span>1975;<span class="ref-vol">32</span>:223–5.</span> [<a href="/pubmed/1124985" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1124985</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.federico.1994.2218">Federico A, Dotti MT. Treatment of cerebrotendinous xanthomatosis. <span><span class="ref-journal">Neurology. </span>1994;<span class="ref-vol">44</span>:2218.</span> [<a href="/pubmed/7970001" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7970001</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.federico.2001.1743">Federico A, Dotti MT. Cerebrotendinous xanthomatosis. <span><span class="ref-journal">Neurology. </span>2001;<span class="ref-vol">57</span>:1743.</span> [<a href="/pubmed/11706139" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11706139</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.federico.2003.633">Federico A, Dotti MT. Cerebrotendinous xanthomatosis: clinical manifestations, diagnostic criteria, pathogenesis, and therapy. <span><span class="ref-journal">J Child Neurol. </span>2003;<span class="ref-vol">18</span>:633–8.</span> [<a href="/pubmed/14572142" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14572142</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.federico.1993.67">Federico A, Dotti MT, Lore F, Nuti R. Cerebrotendinous xanthomatosis: pathophysiological study on bone metabolism. <span><span class="ref-journal">J Neurol Sci. </span>1993;<span class="ref-vol">115</span>:67–70.</span> [<a href="/pubmed/8468594" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8468594</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.federico.1991.734">Federico A, Dotti MT, Volpi N. Muscle mitochondrial changes in cerebrotendinous xanthomatosis. <span><span class="ref-journal">Ann Neurol. </span>1991;<span class="ref-vol">30</span>:734–5.</span> [<a href="/pubmed/1763899" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1763899</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.federico.1987.360">Federico A, Palmeri S, Ciacci G, Rossi A, Malandrini A, Alessandrini C, Salen G, Guazzi GC. Peripheral neuropathy in CTX: seven cases in two families. <span><span class="ref-journal">Neurology. </span>1987;<span class="ref-vol">37</span> Suppl 1:360.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.federico.1989">Federico A. Xantomatosi cerebrotendinea. Aspetti clinici e biochimici. In: Andria G, Dagna Bricarelli F, Del Porto G, De Marchi M, Federico A, eds. <em>Patologia Genetica ad Esordio Tardivo</em>. Bologna, Italy: Monduzzi Ed. 1989:29-38.</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.fiorelli.1990.76">Fiorelli M, Di Piero V, Bastianello S, Bozzao L, Federico A. Cerebrotendinous xanthomatosis: clinical and MRI study (a case report). <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>1990;<span class="ref-vol">53</span>:76–8.</span> [<a href="/pmc/articles/PMC1014102/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1014102</span></a>] [<a href="/pubmed/2303834" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2303834</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.frihayed.2005.992">Frih-Ayed M, Boughammoura-Bouatay A, Ben Hamda K, Chebel S, Ben Farhat M. Hypertrophy of the atrial septum in the cerebrotendinous xanthomatosis. <span><span class="ref-journal">Rev Med Interne. </span>2005;<span class="ref-vol">26</span>:992–3.</span> [<a href="/pubmed/16236394" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16236394</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.fujiyama.1991.1">Fujiyama J, Kuriyama M, Arima S, Shibata Y, Nagata K, Takenaga S, Tanaka H, Osame M. Atherogenic risk factors in cerebrotendinous xanthomatosis. <span><span class="ref-journal">Clin Chim Acta. </span>1991;<span class="ref-vol">200</span>:1–11.</span> [<a href="/pubmed/1934506" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1934506</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.gallus.2006.143">Gallus GN, Dotti MT, Federico A. Clinical and molecular diagnosis of cerebrotendinous xanthomatosis with a review of the mutations in the CYP27A1 gene. <span><span class="ref-journal">Neurol Sci. </span>2006;<span class="ref-vol">27</span>:143–9.</span> [<a href="/pubmed/16816916" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16816916</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.gilad.1999.405">Gilad R, Lampl Y, Lev D, Sadeh M. Cerebrotendinous xanthomatosis without xanthomas. <span><span class="ref-journal">Clin Genet. </span>1999;<span class="ref-vol">56</span>:405–6.</span> [<a href="/pubmed/10668932" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10668932</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.ginanneschi.2013.268">Ginanneschi F, Mignarri A, Mondelli M, Gallus GN, Del Puppo M, Giorgi S, Federico A, Rossi A, Dotti MT. Polyneuropathy in cerebrotendinous xanthomatosis and response to treatment with chenodeoxycholic acid. <span><span class="ref-journal">J Neurol. </span>2013;<span class="ref-vol">260</span>:268–74.</span> [<a href="/pubmed/22878431" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22878431</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.grandas.2002.1396">Grandas F, Martin-Moro M, Garcia-Munozguren S, Anaya F. Early-onset parkinsonism in cerebrotendinous xanthomatosis. <span><span class="ref-journal">Mov Disord. </span>2002;<span class="ref-vol">17</span>:1396–7.</span> [<a href="/pubmed/12465096" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12465096</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.guerrera.2010.1189">Guerrera S, Stromillo ML, Mignarri A, Battaglini M, Marino S, Di Perri C, Federico A, Dotti MT, De Stefano N. Clinical relevance of brain volume changes in patients with cerebrotendinous xanthomatosis. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2010;<span class="ref-vol">81</span>:1189–93.</span> [<a href="/pubmed/20972203" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20972203</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.hansson.2007.504">Hansson M, Olin M, Floren CH, von Bahr S, van't Hooft F, Meaney S, Eggertsen G, Bj&#x000f6;rkhem I. Unique patient with cerebrotendinous xanthomatosis. Evidence for presence of a defect in a gene that is not identical to sterol 27-hydroxylase. <span><span class="ref-journal">J Intern Med. </span>2007;<span class="ref-vol">261</span>:504–10.</span> [<a href="/pubmed/17444890" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17444890</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.hatanaka.1990.390">Hatanaka I, Yasuda H, Hidaka H, Harada N, Kobayashi M, Okabe H, Matsumoto K, Hukuda S, Shigeta Y. Spinal cord compression with paraplegia in xanthomatosis due to normocholesterolemic sitosterolemia. <span><span class="ref-journal">Ann Neurol. </span>1990;<span class="ref-vol">28</span>:390–3.</span> [<a href="/pubmed/2241122" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2241122</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.idouji.1991.402">Idouji K, Kuriyama M, Fujiyama J, Osame M, Hoshita T. Hypothyroidism with increased serum levels of cholestanol and bile alcohol &#x02014; analogous symptoms to cerebrotendinous xanthomatosis. <span><span class="ref-journal">Rinsho Shinkeigaku. </span>1991;<span class="ref-vol">31</span>:402–6.</span> [<a href="/pubmed/1914325" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1914325</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.inglese.2003.495">Inglese M, DeStefano N, Pagani E, Dotti MT, Comi G, Federico A, Filippi M. Quantification of brain damage in cerebrotendinous xanthomatosis with magnetization transfer MR imaging. <span><span class="ref-journal">AJNR Am J Neuroradiol. </span>2003;<span class="ref-vol">24</span>:495–500.</span> [<a href="/pubmed/12637303" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12637303</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.kerleau.1993.1460">Kerleau JM, Lefebvre H, Houdent C, Wolf LM. Early coronary atheroma. A little known complication of cerebrotendinous xanthomatosis. <span><span class="ref-journal">Presse Med. </span>1993;<span class="ref-vol">22</span>:1460.</span> [<a href="/pubmed/8265531" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8265531</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.khan.2013.956">Khan AO, Aldahmesh MA, Mohamed JY, Alkuraya FS. Juvenile cataract morphology in 3 siblings not yet diagnosed with cerebrotendinous xanthomatosis. <span><span class="ref-journal">Ophthalmology. </span>2013;<span class="ref-vol">120</span>:956–60.</span> [<a href="/pubmed/23375591" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23375591</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.ko.2001.30">Ko KF, Lee KW. Cerebrotendinous xanthomatosis in three siblings from a Chinese family. <span><span class="ref-journal">Singapore Med J. </span>2001;<span class="ref-vol">42</span>:30–2.</span> [<a href="/pubmed/11361235" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11361235</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.kuriyama.1991.225">Kuriyama M, Fujiyama J, Yoshidome H, Takenaga S, Matsumuro K, Kasama T, Fukuda K, Kuramoto T, Hoshita T, Seyama Y, Okatu Y, Osame M. Cerebrotendinous xanthomatosis: clinical and biochemical evaluation of eight patients and review of the literature. <span><span class="ref-journal">J Neurol Sci. </span>1991;<span class="ref-vol">102</span>:225–32.</span> [<a href="/pubmed/2072121" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2072121</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.leitersdorf.1993.2488">Leitersdorf E, Reshef A, Meiner V, Levitzki R, Schwartz SP, Dann EJ, Berkman N, Cali JJ, Klapholz L, Berginer VM. Frameshift and splice-junction mutations in the sterol 27-hydroxylase gene cause cerebrotendinous xanthomatosis in Jews of Moroccan origin. <span><span class="ref-journal">J Clin Invest. </span>1993;<span class="ref-vol">91</span>:2488–96.</span> [<a href="/pmc/articles/PMC443309/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC443309</span></a>] [<a href="/pubmed/8514861" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8514861</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.leitersdorf.1994.907">Leitersdorf E, Safadi R, Meiner V, Reshef A, Bjorkhem I, Friedlander Y, Morkos S, Berginer VM. Cerebrotendinous xanthomatosis in the Israeli Druze: molecular genetics and phenotypic characteristics. <span><span class="ref-journal">Am J Hum Genet. </span>1994;<span class="ref-vol">55</span>:907–15.</span> [<a href="/pmc/articles/PMC1918342/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1918342</span></a>] [<a href="/pubmed/7977352" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7977352</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.lorincz.2005.1459">Lorincz MT, Rainier S, Thomas D, Fink JK. Cerebrotendinous xanthomatosis: possible higher prevalence than previously recognized. <span><span class="ref-journal">Arch Neurol. </span>2005;<span class="ref-vol">62</span>:1459–63.</span> [<a href="/pubmed/16157755" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16157755</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.luyckx.2014.9">Luyckx E, Eyskens F, Simons A, Beckx K, Van West D, Dhar M. Long-term follow-up on the effect of combined therapy of bile acids and statins in the treatment of cerebrotendinous xanthomatosis: a case report. <span><span class="ref-journal">Clin Neurol Neurosurg. </span>2014;<span class="ref-vol">118</span>:9–11.</span> [<a href="/pubmed/24529221" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24529221</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.martini.2013.282">Martini G, Mignarri A, Ruvio M, Valenti R, Franci B, Del Puppo M, Federico A, Nuti R, Dotti MT. Long-term bone density evaluation in cerebrotendinous xanthomatosis: evidence of improvement after chenodeoxycholic acid treatment. <span><span class="ref-journal">Calcif Tissue Int. </span>2013;<span class="ref-vol">92</span>:282–6.</span> [<a href="/pubmed/23212544" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23212544</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.matsumuro.1990.207">Matsumuro K, Takahashi K, Matsumoto H, Okatsu Y, Kuriyama M. <span><span class="ref-journal">Rinsho Shinkeigaku. </span>1990;<span class="ref-vol">30</span>:207–9.</span> [A case of cerebrotendinous xanthomatosis with convulsive seizures] [<a href="/pubmed/2190743" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2190743</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.mignarri.2012a.649">Mignarri A, Dotti MT, Del Puppo M, Gallus GN, Giorgio A, Cerase A, Monti L. Cerebrotendinous xanthomatosis with progressive cerebellar vacuolation : six-year MRI follow-up. <span><span class="ref-journal">Neuroradiology. </span>2012a;<span class="ref-vol">54</span>:649–51.</span> [<a href="/pubmed/22415344" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22415344</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.mignarri.2012b.99">Mignarri A, Falcini M, Vella A, Giorgio A, Gallus GN, Del Puppo M, Vattimo A, Federico A, Dotti MT. Parkinsonism as neurological presentation of late-onset cerebrotendinous xanthomatosis. <span><span class="ref-journal">Parkinsonism Relat Disord. </span>2012b;<span class="ref-vol">18</span>:99–101.</span> [<a href="/pubmed/21764626" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21764626</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.mignarri.2014.421">Mignarri A, Gallus GN, Dotti MT, Federico A. A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis. <span><span class="ref-journal">J Inherit Metab Dis. </span>2014;<span class="ref-vol">37</span>:421–9.</span> [<a href="/pubmed/24442603" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24442603</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.mignarri.2011.783">Mignarri A, Rossi S, Ballerini M, Gallus GN, Del Puppo M, Galluzzi P, Federico A, Dotti MT. Clinical relevance and neurophysiological correlates of spasticity in cerebrotendinous xanthomatosis. <span><span class="ref-journal">J Neurol. </span>2011;<span class="ref-vol">258</span>:783–90.</span> [<a href="/pubmed/21104094" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21104094</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.mimura.1993.227">Mimura Y, Kuriyama M, Tokimura Y, Fujiyama J, Osame M, Takesako K, Tanaka N. Treatment of cerebrotendinous xanthomatosis with low-density lipoprotein (LDL)-apheresis. <span><span class="ref-journal">J Neurol Sci. </span>1993;<span class="ref-vol">114</span>:227–30.</span> [<a href="/pubmed/8445406" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8445406</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.moghadasian.2004.42">Moghadasian MH. Cerebrotendinous xanthomatosis: clinical course, genotypes and metabolic backgrounds. <span><span class="ref-journal">Clin Invest Med. </span>2004;<span class="ref-vol">27</span>:42–50.</span> [<a href="/pubmed/15061585" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15061585</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.mondelli.1992.469">Mondelli M, Rossi A, Scarpini C, Dotti MT, Federico A. Evoked potentials in cerebrotendinous xanthomatosis and effect induced by chenodeoxycholic acid. <span><span class="ref-journal">Arch Neurol. </span>1992;<span class="ref-vol">49</span>:469–75.</span> [<a href="/pubmed/1316120" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1316120</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.mondelli.2001.29">Mondelli M, Sicurelli F, Scarpini C, Dotti MT, Federico A. Cerebrotendinous xanthomatosis: 11-year treatment with chenodeoxycholic acid in five patients. An electrophysiological study. <span><span class="ref-journal">J Neurol Sci. </span>2001;<span class="ref-vol">190</span>:29–33.</span> [<a href="/pubmed/11574103" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11574103</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.morgan.1989.1011">Morgan SJ, McKenna P, Bosanquet RC. Case of cerebrotendinous xanthomatosis. I: Unusual ophthalmic features. <span><span class="ref-journal">Br J Ophthalmol. </span>1989;<span class="ref-vol">73</span>:1011–4.</span> [<a href="/pmc/articles/PMC1041958/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1041958</span></a>] [<a href="/pubmed/2611184" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2611184</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.nagai.1996.571">Nagai Y, Hirano M, Mori T, Takakura Y, Tamai S, Ueno S. Japanese triplets with cerebrotendinous xanthomatosis are homozygous for a mutant gene coding for the sterol 27-hydroxylase (Arg441Trp). <span><span class="ref-journal">Neurology. </span>1996;<span class="ref-vol">46</span>:571–4.</span> [<a href="/pubmed/8614539" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8614539</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.ohnishi.1979.43">Ohnishi A, Yamashita Y, Goto I, Kuroiwa Y, Murakami S, Ikeda M. De- and remyelination and onion bulb in cerebrotendinous xanthomatosis. <span><span class="ref-journal">Acta Neuropathol (Berl). </span>1979;<span class="ref-vol">45</span>:43–5.</span> [<a href="/pubmed/760364" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 760364</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.ohno.2001.95">Ohno T, Kobayashi S, Hayashi M, Sakurai M, Kanazawa I. Diphenylpyraline-responsive parkinsonism in cerebrotendinous xanthomatosis: long-term follow up of three patients. <span><span class="ref-journal">J Neurol Sci. </span>2001;<span class="ref-vol">182</span>:95–7.</span> [<a href="/pubmed/11137513" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11137513</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.pastershank.1974.282">Pastershank SP, Yip S, Sodhi HS. Cerebrotendinous xanthomatosis. <span><span class="ref-journal">J Can Assoc Radiol. </span>1974;<span class="ref-vol">25</span>:282–6.</span> [<a href="/pubmed/4443363" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4443363</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.peynet.1991.434">Peynet J, Laurent A, De Liege P, Lecoz P, Gambert P, Legrand A, Mikol J, Warnet A. Cerebrotendinous xanthomatosis: treatments with simvastatin, lovastatin, and chenodeoxycholic acid in 3 siblings. <span><span class="ref-journal">Neurology. </span>1991;<span class="ref-vol">41</span>:434–6.</span> [<a href="/pubmed/2006015" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2006015</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.philippart.1969.603">Philippart M, Van Bogaert L. Cholestanolosis (cerebrotendinous xanthomatosis). A follow-up study on the original family. <span><span class="ref-journal">Arch Neurol. </span>1969;<span class="ref-vol">21</span>:603–10.</span> [<a href="/pubmed/5355255" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5355255</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.pierre.2008.s241">Pierre G, Setchell K, Blyth J, Preece MA, Chakrapani A, McKiernan P. Prospective treatment of cerebrotendinous xanthomatosis with cholic acid therapy. <span><span class="ref-journal">J Inherit Metab Dis. </span>2008;<span class="ref-vol">31</span> Suppl 2:S241–5.</span> [<a href="/pubmed/19125350" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19125350</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.pilodelafuente.2011.1203">Pilo-de-la-Fuente B, Jimenez-Escrig A, Lorenzo JR, Pardo J, Arias M, Ares-Luque A, Duarte J, Mu&#x000f1;iz-P&#x000e9;rez S, Sobrido MJ. Cerebrotendinous xanthomatosis in Spain: clinical, prognostic, and genetic survey. <span><span class="ref-journal">Eur J Neurol. </span>2011;<span class="ref-vol">18</span>:1203–11.</span> [<a href="/pubmed/21645175" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21645175</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.rogelet.1992.541">Rogelet P, Gerard JM, Michotte A, Masingue M, Destee A. Cerebrotendinous xanthomatosis. 2 cases with magnetic resonance imaging. <span><span class="ref-journal">Rev Neurol (Paris). </span>1992;<span class="ref-vol">148</span>:541–5.</span> [<a href="/pubmed/1494725" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1494725</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.rystedt.2002.259">Rystedt E, Olin M, Seyama Y, Buchmann M, Berstad A, Eggertsen G, Bjorkhem I. Cerebrotendinous xanthomatosis: molecular characterization of two Scandinavian sisters. <span><span class="ref-journal">J Intern Med. </span>2002;<span class="ref-vol">252</span>:259–64.</span> [<a href="/pubmed/12270007" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12270007</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.salen.1978.82">Salen G, Zaki FG, Sabesin S, Boehme D, Shefer S, Mosbach EH. Intrahepatic pigment and crystal forms in patients with cerebrotendinous xanthomatosis (CTX). <span><span class="ref-journal">Gastroenterology. </span>1978;<span class="ref-vol">74</span>:82–9.</span> [<a href="/pubmed/618433" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 618433</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.schimschock.1968.688">Schimschock JR, Alvord EC Jr, Swanson PD. Cerebrotendinous xanthomatosis. Clinical and pathological studies. <span><span class="ref-journal">Arch Neurol. </span>1968;<span class="ref-vol">18</span>:688–98.</span> [<a href="/pubmed/5652996" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5652996</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.schreiner.1975.405">Schreiner A, Hopen G, Skrede S. Cerebrotendinous xanthomatosis (cholestanolosis). Investigations on two sisters and their family. <span><span class="ref-journal">Acta Neurol Scand. </span>1975;<span class="ref-vol">51</span>:405–16.</span> [<a href="/pubmed/1130172" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1130172</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.sugama.2001.379">Sugama S, Kimura A, Chen W, Kubota S, Seyama Y, Taira N, Eto Y. Frontal lobe dementia with abnormal cholesterol metabolism and heterozygous mutation in sterol 27-hydroxylase gene (CYP27). <span><span class="ref-journal">J Inherit Metab Dis. </span>2001;<span class="ref-vol">24</span>:379–92.</span> [<a href="/pubmed/11486904" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11486904</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.tint.1989.633">Tint GS, Ginsberg H, Salen G, Le NA, Shefer S. Chenodeoxycholic acid normalizes elevated lipoprotein secretion and catabolism in cerebrotendinous xanthomatosis. <span><span class="ref-journal">J Lipid Res. </span>1989;<span class="ref-vol">30</span>:633–40.</span> [<a href="/pubmed/2760539" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2760539</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.valdivielso.2004.680">Valdivielso P, Calandra S, Duran JC, Garuti R, Herrera E, Gonzalez P. Coronary heart disease in a patient with cerebrotendinous xanthomatosis. <span><span class="ref-journal">J Intern Med. </span>2004;<span class="ref-vol">255</span>:680–3.</span> [<a href="/pubmed/15147532" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15147532</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.van_bogaert.1962.433">Van Bogaert L. The framework of the xanthomatoses and their different types. 2. Secondary xanthomatoses. <span><span class="ref-journal">Rev Med Liege. </span>1962;<span class="ref-vol">17</span>:433–43.</span> [<a href="/pubmed/13924474" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13924474</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.van_bogaert.1937">Van Bogaert L, Scherer HJ, Epstein E. <em>Une Forme Cerebrale de la Cholesterinose Generalisee</em>. Paris, France: Masson et Cie; 1937.</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.verrips.2000a.908">Verrips A, Hoefsloot LH, Steenbergen GC, Theelen JP, Wevers RA, Gabreels FJ, van Engelen BG, van den Heuvel LP. Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. <span><span class="ref-journal">Brain. </span>2000a;<span class="ref-vol">123</span>:908–19.</span> [<a href="/pubmed/10775536" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10775536</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.verrips.1999a.1589">Verrips A, Nijeholt GJ, Barkhof F, Van Engelen BG, Wesseling P, Luyten JA, Wevers RA, Stam J, Wokke JH, van den Heuvel LP, Keyser A, Gabreels FJ. Spinal xanthomatosis: a variant of cerebrotendinous xanthomatosis. <span><span class="ref-journal">Brain. </span>1999a;<span class="ref-vol">122</span>:1589–95.</span> [<a href="/pubmed/10430841" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10430841</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.verrips.2000b.407">Verrips A, van Engelen BG, ter Laak H, Gabreels-Festen A, Janssen A, Zwarts M, Wevers RA, Gabreels FJ. Cerebrotendinous xanthomatosis. Controversies about nerve and muscle: observations in ten patients. <span><span class="ref-journal">Neuromuscul Disord. </span>2000b;<span class="ref-vol">10</span>:407–14.</span> [<a href="/pubmed/10899446" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10899446</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.verrips.2000c.520">Verrips A, van Engelen BG, Wevers RA, van Geel BM, Cruysberg JR, van den Heuvel LP, Keyser A, Gabreels FJ. Presence of diarrhea and absence of tendon xanthomas in patients with cerebrotendinous xanthomatosis. <span><span class="ref-journal">Arch Neurol. </span>2000c;<span class="ref-vol">57</span>:520–4.</span> [<a href="/pubmed/10768627" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10768627</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.verrips.1999b.233">Verrips A, Wevers RA, Van Engelen BG, Keyser A, Wolthers BG, Barkhof F, Stalenhoef A, De Graaf R, Janssen-Zijlstra F, Van Spreeken A, Gabreels FJ. Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis. <span><span class="ref-journal">Metabolism. </span>1999b;<span class="ref-vol">48</span>:233–8.</span> [<a href="/pubmed/10024088" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10024088</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.waterreus.1987.169">Waterreus RJ, Koopman BJ, Wolthers BG, Oosterhuis HJ. Cerebrotendinous xanthomatosis (CTX): a clinical survey of the patient population in The Netherlands. <span><span class="ref-journal">Clin Neurol Neurosurg. </span>1987;<span class="ref-vol">89</span>:169–75.</span> [<a href="/pubmed/3665290" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3665290</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="ctx.REF.yahalom.2013.78">Yahalom G, Tsabari R, Molshatzki N, Ephraty L, Cohen H, Hassin-Baer S. Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis. <span><span class="ref-journal">Clin Neuropharmacol. </span>2013;<span class="ref-vol">36</span>:78–83.</span> [<a href="/pubmed/23673909" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23673909</span></a>]</div></li></ul></div></div><div id="ctx.Chapter_Notes"><h2 id="_ctx_Chapter_Notes_">Chapter Notes</h2><div id="ctx.Author_Notes"><h3>Author Notes</h3><p>Antonio Federico is a full professor of Clinical Neurology and Director of the Department of Neurological and Behavioral Sciences, University of Siena. Maria Teresa Dotti is an associate professor at the University of Siena. Gian Nicola Gallus is a PhD student in the PhD Program of Applied Neurological Sciences, Department of Neurological and Behavioral Sciences, University of Siena.</p></div><div id="ctx.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>14 April 2016 (ma) Comprehensive update posted live</div></li><li class="half_rhythm"><div>1 August 2013 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>20 October 2011 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> available clinically</div></li><li class="half_rhythm"><div>16 November 2010 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>25 January 2008 (cd) Revision: prenatal testing available</div></li><li class="half_rhythm"><div>7 February 2006 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>16 July 2003 (me) Review posted live</div></li><li class="half_rhythm"><div>18 December 2002 (af) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1409</span><span class="label">PMID: <a href="/pubmed/20301583" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301583</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/ccm/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/char/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1409&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1409/?report=reader">PubReader</a></li><li><a href="/books/NBK1409/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1409" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1409" style="display:none" title="Cite this Page"><div class="bk_tt">Federico A, Dotti MT, Gallus GN. Cerebrotendinous Xanthomatosis. 2003 Jul 16 [Updated 2016 Apr 14]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1409/pdf/Bookshelf_NBK1409.pdf">PDF version of this page</a> (638K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#ctx.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#ctx.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#ctx.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#ctx.Genetically_Related_Allelic_Disorder" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#ctx.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#ctx.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#ctx.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#ctx.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#ctx.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#ctx.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#ctx.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=1593[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">CYP27A1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK1409+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1494514" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1494514" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1494514" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1494514" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/22791847" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Cerebrotendinous xanthomatosis associated with immune thrombocytopenia.</a><span class="source">[BMJ Case Rep. 2010]</span><div class="brieflinkpop offscreen_noflow">Cerebrotendinous xanthomatosis associated with immune thrombocytopenia.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">El Husseiny NM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">BMJ Case Rep. 2010 Nov 5; 2010. Epub 2010 Nov 5.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25424010" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management.</a><span class="source">[Orphanet J Rare Dis. 2014]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Nie S, Chen G, Cao X, Zhang Y. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Orphanet J Rare Dis. 2014 Nov 26; 9:179. Epub 2014 Nov 26.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/1908036" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis.</a><span class="source">[Metabolism. 1991]</span><div class="brieflinkpop offscreen_noflow">Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Nakamura T, Matsuzawa Y, Takemura K, Kubo M, Miki H, Tarui S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Metabolism. 1991 Jul; 40(7):741-6. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28229379" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">A novel frameshift mutation in the sterol 27-hydroxylase gene in an Egyptian family with cerebrotendinous xanthomatosis without cataract.</a><span class="source">[Metab Brain Dis. 2017]</span><div class="brieflinkpop offscreen_noflow">A novel frameshift mutation in the sterol 27-hydroxylase gene in an Egyptian family with cerebrotendinous xanthomatosis without cataract.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Abdel-Hamid MS, Issa MY, Otaify GA, Zaki MS. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Metab Brain Dis. 2017 Apr; 32(2):311-315. Epub 2017 Feb 22.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28980151" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX).</a><span class="source">[J Inherit Metab Dis. 2017]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX).<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Salen G, Steiner RD. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Inherit Metab Dis. 2017 Nov; 40(6):771-781. Epub 2017 Oct 4.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301583" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301583" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e041a0439a66ee2ba6474e7">Cerebrotendinous Xanthomatosis - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Cerebrotendinous Xanthomatosis - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:25:08-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal102&amp;ncbi_phid=CE89BF73E04154C10000000002700114&amp;ncbi_session=CE89BF73E041A031_0624SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1409%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1409&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1409/&amp;ncbi_pagename=Cerebrotendinous Xanthomatosis - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE89BF73E041A031_0624SID /projects/books/PBooks@5.22 portal102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>